Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. - Wikidata - awgldk - TriplyDB

Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.

Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.

http://www.wikidata.org/entity/Q34134694

about

Endothelin The emerging roles of β-arrestins in fibrotic diseases Gaddum Memorial Lecture 2014: receptors as an evolving concept: from switches to biased microprocessors Non-traditional roles of G protein-coupled receptors in basic cell biology Impedance responses reveal β₂-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles Potential new drug treatments for congestive heart failure.Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR)G protein-coupled receptors in cardiac biology: old and new receptors Nonhematopoietic β-Arrestin-1 inhibits inflammation in a murine model of polymicrobial sepsis.Biased signaling favoring gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis.Allosteric modulation of β-arrestin-biased angiotensin II type 1 receptor signaling by membrane stretch.The potential for selective pharmacological therapies through biased receptor signaling Identification of serine 348 on the apelin receptor as a novel regulatory phosphorylation site in apelin-13-induced G protein-independent biased signaling.Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis.ERK5 activation by Gq-coupled muscarinic receptors is independent of receptor internalization and β-arrestin recruitment Quantifying ligand bias at seven-transmembrane receptors.Investigation of the fate of type I angiotensin receptor after biased activation Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2.Different downstream signalling of CCK1 receptors regulates distinct functions of CCK in pancreatic beta cells Comparative analyses of downstream signal transduction targets modulated after activation of the AT1 receptor by two β-arrestin-biased agonists.Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model.Multiple ligand-specific conformations of the β2-adrenergic receptor International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].β-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury.The role of β-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome.Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.G Protein-coupled Receptor Biased Agonism.Structure-activity relationship study of angiotensin II analogs in terms of β-arrestin-dependent signaling to aldosterone production.Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors Therapeutic potential of β-arrestin- and G protein-biased agonists.On the selectivity of the Gαq inhibitor UBO-QIC: A comparison with the Gαi inhibitor pertussis toxin.Quantification of mutation-derived bias for alternate mating functionalities of the Saccharomyces cerevisiae Ste2p pheromone receptor Mechanisms of Biased β-Arrestin-Mediated Signaling Downstream from the Cannabinoid 1 Receptor.Arginine vasopressin enhances cell survival via a G protein-coupled receptor kinase 2/β-arrestin1/extracellular-regulated kinase 1/2-dependent pathway in H9c2 cells.Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium

P2860

Q26767156-388419F1-3317-4627-9327-411EC9E92CD4 Q26783047-F7E74528-75D6-4E49-B3FE-60C358628E4F Q27005640-9BACA7EE-0601-44C4-9099-795C359ACC1B Q27006799-B03CFB94-BF26-42D6-89A9-F0B750DF48F6 Q28478728-B6B03507-5A19-4D39-BCB9-1657A0267088 Q30251531-C8D3A632-0D87-4263-A2BA-D4A90C4111EE Q33619504-0A587763-1724-4EE0-A27B-F3726816D7E0 Q33639685-0D38E5F4-078F-4108-A82E-52EB6C4B02A7 Q33978110-06B014DB-CCAF-4870-B612-2CC88A1A7B3E Q34107370-110766C3-E7EB-496C-83F8-3B64F49FFFFA Q34249203-30E15DC1-5036-4BFC-B1E5-21ED32708C62 Q34317331-2B783E25-7A50-4AF7-993A-99378387C928 Q34402658-F3E209C9-7847-480B-982E-749CA5B40909 Q34467542-0D8D5067-8B2E-4355-91C0-0C0B4B2A1876 Q34624192-8508F705-4B01-48EC-94F3-1A135494D7AB Q35073274-58F2D55A-823A-4E8E-8F6F-0D0F7DF08369 Q35188090-09E98132-034F-4C76-8553-C73807791557 Q35600402-6A2678D8-7779-49B8-98C1-776E461584E3 Q35738904-5591F596-DE64-404D-A320-8EE87B1119FD Q35739137-123FB724-BD3C-4216-87B3-68A6D7150C61 Q35802560-5D658A11-6617-4BE4-AE69-5A60B87EE0D5 Q36048967-90BD4878-E1AC-4134-8EF1-CCE27238CE24 Q36115098-C63B652F-09B9-4494-8A5A-EF685F5A27B1 Q36241932-21B1FBB4-9BAA-46CB-9BA5-81C8C4793295 Q36312524-1C89A394-9985-4F6D-9D37-1B8ABBF40F6B Q36339426-D2519AB4-51D1-4E8E-9F5B-F44D327F632C Q36347742-E54BFEC3-A64C-4901-BDBC-1547E7E7E37E Q36446506-E8EE8F5F-2621-44AE-953E-E2EF6B952D6C Q36551388-D62691CC-0D63-4AA1-83BC-27101772ACB3 Q36665235-BA2245FE-DC5F-40C3-9BFF-EDE178B669D6 Q36719641-06B53434-ED3D-4095-B735-9AE1F4FAAC09 Q36773326-E6A24B04-6C7F-46AA-8E70-70A774986A05 Q36773331-80DA693F-6CC7-4FAF-B2B6-809CAA93BD7E Q36821853-B607D33D-B648-4C43-B0F7-8B37BB965A65 Q36941643-4F2476F8-DD51-439B-9EB6-9140EEA43E28 Q36947742-D91FE4E9-841A-4358-8206-332ECE6B7670 Q37027076-0C14A4BE-F144-4606-A511-EFE5FFB04076 Q37062531-1EFB4C1D-B81B-43E3-BF25-AE60142CDDB4 Q37102508-FCF06872-B993-4166-A6D6-30A9FA0C1BC3 Q37142798-512437C9-3144-4E8F-9036-6A7B851EB3E0

P2860

Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance.

http://www.wikidata.org/entity/Q34134694

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Selectively engaging β-arresti ...... increases cardiac performance.

@ast

Selectively engaging β-arresti ...... increases cardiac performance.

@en

Selectively engaging β-arresti ...... increases cardiac performance.

@nl

type

label

Selectively engaging β-arresti ...... increases cardiac performance.

@ast

Selectively engaging β-arresti ...... increases cardiac performance.

@en

Selectively engaging β-arresti ...... increases cardiac performance.

@nl

prefLabel

Selectively engaging β-arresti ...... increases cardiac performance.

@ast

Selectively engaging β-arresti ...... increases cardiac performance.

@en

Selectively engaging β-arresti ...... increases cardiac performance.

@nl

P1433

Q34134694-80A153BD-1EA8-4ECD-B13F-B1EBD9D149C1

P1476

Q34134694-D50A08BF-6902-425F-957A-F2C007FE0E8B

P2093

Q34134694-100012E8-CA3B-4571-A8C3-CFCCFCAF74F2

Q34134694-1D5F8BF3-BF83-4181-972A-C348D3ACA373

Q34134694-4CF2D9A3-C69D-4A06-BF21-0F75CA5918FC

Q34134694-7BAD384C-43C8-4685-92BF-F7BDF35594D5

Q34134694-AD45DFAB-F038-4440-872C-A2A0B715C695

Q34134694-B411D3EC-E527-4A46-B660-7AC6D25E30BC

Q34134694-D81156EB-90C4-480C-8EA9-6B37795FEDEE

Q34134694-D8CCC4F7-303A-4FD3-8711-B48377A415EA

P304

Q34134694-20CAE121-FF27-4BC7-BDB5-25F2947571C8

P31

Q34134694-F6E37372-775A-4C12-B3AB-FB8A90C4DEC1

P356

Q34134694-1289400D-7E36-4EF2-BAD3-9E6AD01430B6

P407

Q34134694-4D66C0F3-D6EB-4AFC-BED7-947EEEC11E56

P433

Q34134694-ABED94C2-FE5B-4BAA-A6F6-75C1A2950173

P478

Q34134694-2BCADCC7-4FE5-416F-BD2F-48BD4FCC40C8

P50

Q34134694-6DBC26AD-95CD-4A02-A382-AEEDF7BA0A3E

P577

Q34134694-C28ECEE5-F773-493C-9820-02A4A255F36D

P698

Q34134694-3CF20CE7-BDA2-4DB8-8C4E-FA8990B0A65F

P356

JPET.110.173005

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Selectively engaging β-arresti ...... increases cardiac performance

@en

P2093

David H Rominger

http://www.w3.org/2001/XMLSchema#string

Dennis Yamashita

http://www.w3.org/2001/XMLSchema#string

Erin J Whalen

http://www.w3.org/2001/XMLSchema#string

Jonathan D Violin

http://www.w3.org/2001/XMLSchema#string

Kevin Schiller

http://www.w3.org/2001/XMLSchema#string

Lisa Nguyen

http://www.w3.org/2001/XMLSchema#string

Maxine Gowen

http://www.w3.org/2001/XMLSchema#string

Michael W Lark

http://www.w3.org/2001/XMLSchema#string

P304

572-579

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.110.173005

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

335

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20801892

http://www.w3.org/2001/XMLSchema#string